Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Retained Earnings (2022 - 2026)

Compass Therapeutics' Retained Earnings history spans 5 years, with the latest figure at -$449.5 million for Q1 2026.

  • On a quarterly basis, Retained Earnings fell 236673.16% to -$449.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$449.5 million, a 236673.16% decrease, with the full-year FY2025 number at $280000.0, up 33.33% from a year prior.
  • Retained Earnings hit -$449.5 million in Q1 2026 for Compass Therapeutics, down from $280000.0 in the prior quarter.
  • Over the last five years, Retained Earnings for CMPX hit a ceiling of $486000.0 in Q3 2024 and a floor of -$449.5 million in Q1 2026.
  • Historically, Retained Earnings has averaged -$153.3 million across 5 years, with a median of -$288000.0 in 2023.
  • The widest YoY moves for Retained Earnings: up 311.11% in 2025, down 440775.82% in 2025.
  • Tracing CMPX's Retained Earnings over 5 years: stood at -$272.8 million in 2022, then decreased by 15.58% to -$315.3 million in 2023, then surged by 100.07% to $210000.0 in 2024, then soared by 33.33% to $280000.0 in 2025, then plummeted by 160631.79% to -$449.5 million in 2026.
  • Business Quant data shows Retained Earnings for CMPX at -$449.5 million in Q1 2026, $280000.0 in Q4 2025, and -$415.5 million in Q3 2025.